t
ECO Animal Health Group PLC filed a Block Listing Return on 29 April 2022 for its Executive Share Option Scheme and Unapproved Share Option Scheme. The return covered the period from 1 May 2021 to 29 April 2022. During this period, 17,500 ordinary shares were issued/allotted under the schemes, resulting in a balance of 375,505 unallotted shares.
| Date | 29 Apr 2022 |
| Time | 11:47:04 |
| Category | Capital structure |
| ID | 8952J |
29 April 2022
ECO Animal Health Group PLC
BLOCK LISTING RETURN
Date: 29 April 2022
|
Name of applicant: |
ECO Animal Health Group plc |
|||
|
Name of scheme: |
Executive Share Option Scheme and Unapproved Share Option Scheme |
|||
|
Number and class of securities originally listed and the date of admission: |
1,500,000 ordinary shares of 5 pence each on 20 July 2017 |
|||
|
Period of return: |
From: |
1 May 2021 |
To: |
29 April 2022 |
|
Balance of unallotted securities under scheme(s) from previous return: |
393,005 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
0 |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period: |
17,500 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
375,505
|
|||
|
|
|
|
|
|
For further information, please contact:
|
ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
|
|
|
IFC Advisory Graham Herring Zach Cohen
|
020 3934 6630
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas
|
020 7496 3000 |
|
Investec (Joint Broker) Gary Clarence Alex Penney Carlo Spingardi
Peel Hunt LLP (Joint Broker) Dr Christopher Golden James Steel |
020 7597 5970
020 7418 8900 |
|
Equity Developments Hannah Crowe Matt Evans |
020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.